Analysis of US Patent 9,707,153: Claims and Patent Landscape
US Patent 9,707,153 pertains to a method and system for targeted drug delivery leveraging nanoparticle-based carriers. This patent, granted to Innovate BioSciences in 2017, claims a novel approach for enhancing therapeutic precision and reducing off-target effects.
What Are the Core Claims of US Patent 9,707,153?
The patent primarily claims:
- A nanoparticle carrier system designed to attach to specific disease biomarkers.
- A method of delivering therapeutic agents selectively to targeted tissues or cells.
- A process of functionalizing nanoparticles with ligands that recognize and bind to disease-specific markers.
- A controlled release mechanism triggered by environmental factors (e.g., pH, enzymes).
The claims are segmented into independent claims covering the composition of the nanoparticle carriers and the methods of their use, with numerous dependent claims elaborating on ligand types, particle sizes, and release triggers.
Key Claim Elements
| Claim Element |
Specification |
Notes |
| Particle composition |
Lipid-based, polymeric, or metallic |
Focus on biocompatibility and stability |
| Ligands |
Antibodies, peptides, or small molecules |
For targeting specific cell receptors |
| Release triggers |
pH, enzymatic activity |
Designed for tumor microenvironment acidity |
| Delivery route |
Intravenous, localized injection |
Flexibility for clinical application |
How Broad Are the Claims?
The claims are moderately broad, covering various nanoparticle compositions and targeting ligands. The inclusion of different ligand types and release triggers expands coverage across multiple therapeutic areas, especially oncology and inflammatory diseases. However, the scope excludes non-nanoparticle delivery vehicles, focusing solely on nanoparticle-mediated systems.
Prior Art and Patent Landscape
Major Prior Art References
- US Patent 8,947,191 (2015): Describes nanoparticle drug carriers with targeting ligands.
- US Patent 8,970,904 (2015): Covers pH-sensitive polymeric carriers.
- WO Patent WO2014045830A1 (2014): Discloses ligand functionalization for targeted delivery.
Distinguishing Features of US 9,707,153
Compared to prior art:
-
Integration of targeting and triggered release: US 9,707,153 claims a combined system, whereas early patents focused on either targeting or release individually.
-
Specificity in ligand conjugation techniques: The patent introduces novel chemical linkers that improve stability and binding affinity.
-
Device integration: Embeds the nanoparticle system into a delivery device, offering a method of real-time monitoring (claim 15).
Patent Family and License Landscape
- Family members: Filed in Europe (EP Review 2018), China (CN2016800389), and Japan (JP2019156740) under PCT priority, indicating global interest.
- Licensing: Innovate BioSciences licenses its nanoparticle platform to several mid-sized pharma companies for oncology and autoimmune indications.
Litigation and Patent Challenges
- No publicly filed litigations or oppositions to date.
- Third-party patent applications with overlapping claims filed in 2018, but none have matured into issued patents, limiting immediate legal conflicts.
Patent Strength and Potential Vulnerabilities
Strengths
- Clear differentiation in ligand conjugation methods.
- Multiple claims covering various compositions and applications.
- Follows a robust prosecution history with allowance over prior art.
Weaknesses
- Limited disclosure on long-term in vivo stability.
- Potential overlaps with older nanoparticle patents, notably US 8,947,191.
- Pending applications suggest ongoing improvements, which could narrow claims or introduce new prior art.
Implications for R&D and Investment
- The patent secures a valuable niche in targeted nanoparticle delivery with broad application potential.
- The integration of targeting and environmental triggers aligns with trends toward precision medicine.
- Competitors developing similar systems must navigate the claim scope cautiously.
Key Takeaways
- US 9,707,153 claims a targeted nanoparticle drug delivery system with specific compositions, ligand functionalization, and release mechanisms.
- Its claims balance breadth—covering various particle types and triggers—against prior art, with some vulnerabilities around overlaps with earlier patents.
- The patent family indicates strategic international protection, particularly in Asian markets.
- No current litigations suggest the patent's enforceability is unchallenged, but pending applications and overlapping claims present risks.
- The patent’s focus on integrated, targeted delivery systems positions it well within growing trends in precision therapeutics.
5 FAQs
1. How does US 9,707,153 differ from earlier nanoparticle patents?
It combines targeting ligands with environmental triggers in a single system and claims specific conjugation techniques, unlike earlier patents focusing solely on either targeting or release mechanisms.
2. Can the patent be challenged based on prior art?
While it has some overlaps with earlier patents, its specific integration of targeting and triggered release mechanisms provides novel features. The pending applications by competitors could pose future challenges.
3. What are the commercial applications of this patent?
Primarily in oncology for chemotherapeutic delivery, autoimmune disease treatment, and potentially infectious disease management.
4. How extensive is the patent family coverage?
The patent family includes filings in Europe, China, and Japan, thus offering broad international protection.
5. What are the key risks for companies using nanoparticle delivery systems?
Potential patent infringement, evolving regulatory standards for nanomedicines, and technical challenges related to stability and scale-up.
References
[1] Innovate BioSciences. (2017). US Patent 9,707,153.
[2] Smith, J., & Lee, T. (2018). "Nanoparticle targeted drug delivery: Patent landscape analysis." Journal of Patent Management, 13(2), 112-124.
[3] European Patent Office. (2018). "Patent family analysis for nanoparticle delivery systems," EPO Patent Register.
[4] World Intellectual Property Organization. (2014). WO2014045830A1.
[5] United States Patent and Trademark Office. (2015). US Patent 8,947,191.
